[Education, graduate and continuing education].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R Baumgarten.
Explore the source record for details and available documents.
By means of the replication cycle of human immunodeficiency virus (HIV) some starting points for antiviral chemicals are outlined. Only azidothymidine is approved yet for treatment of AIDS patients. It restrains virus multiplication, improves the general immunologic situation, and in case of HIV encephalopathy it leads to marked clinical improvement. However, the indications of azidothymidine are limited by its unwanted side reactions. Seemingly the therapeutic effect is only a temporary one. Contagiosity of treated patients remains unaffected. Out of the bulk of chemicals now under investigation in laboratory and clinic those should have the best chance to be successful which interfere with protein products of the viral control genes.
Pharmacokinetic studies with sulfamethazine (500 mg) and antipyrine (15 mg/kg) were performed in 27 hypertonic patients (16 females, 11 males, 37-78 years) who had recovered from a dihydralazine-induced hepatitis, and 21 patients with essential hypertension (13 females, 8 males, 18-74 years) treated with antihypertonics excluding dihydralazine. 20 patients of the hepatitis group (74%) and 12 patients of the control group (57%) were slow acetylators. With regard to the pharmacokinetic parameters no differences were found in both slow and rapid acetylators between the sulfamethazine group and the antipyrine group.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The discovery of the Human Immunodeficiency Virus (HIV), the characterization of its molecular biology and the development of serologic methods for detecting antibodies have led to a better understanding of HIV-associated clinical syndromes. Recently, the Centre of Disease Control has proposed a classification of HIV-related conditions. This classification forms the basis for this review. It is completed by remarks on antiviral and immunomodulating drugs and its effects on HIV. Difficulties in development of vaccines are discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Bone marrow aplasia associated with acute viral hepatitis is a rare, in the rule late complication. A prognostic relation between the latency of acute hepatitis and the development of aplastic anemia is described. We report a case of nearly symptomless hepatitis in a 25 year old women with a fatal course of aplastic anemia. First clinical symptoms were caused by aplastic anemia. The pathogenesis of aplastic anemia associated to viral hepatitis is obscure. Genetic and immunological causes are discussed. A direct viral action is possible. Because the main part of the described cases is caused by non-A, non-B hepatitis, it seems apparent that at least a non-A, non-B virus strain could have an affinity to bone marrow cells. Ensuring this, relations will be impossible up to the identification of the virus.
Explore the source record for details and available documents.
Explore the source record for details and available documents.